Q-omics provides the consensus-scored LINC01194 profile across patient tissues and cancer cell-line models. LINC01194 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01194 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, LINC01194 RNA expression shows 6,208 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LIHC, and TGCT as cancer lineages where LINC01194 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01194 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01194 survival associations across molecular data types. LINC01194 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01194 RNA expression–survival associations across cancer types. High LINC01194 expression shows unfavorable associations in KIRP, KIRC, UVM, READ, PAAD and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01194 RNA expression.
This table summarizes LINC01194 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01194. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01194 shows higher tumor expression in LIHC, HNSC, BRCA, LUSC, LUAD and PRAD. The LIHC box plot shows higher LINC01194 RNA expression in tumor versus normal tissue (log2 FC = +0.684, t-test p < 0.001).
This table shows molecular features associated with LINC01194 in patient tissues and cancer cell lines. In patient samples, LINC01194 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
